Table 3. Study endpoints.

Efficacy outcome

Primary: rate of LVT resolution after triple antithrombotic therapy for 3 months

Secondary: (I) time to LVT resolution. (II) Incidence of any systemic embolic events within 3 months and 1 year after triple therapy. (III) Incidence of composite adverse events including all-cause death, recurrent myocardial infarct, systemic embolism within 3 months and 1 year

Safety outcome

Primary: incidence of major bleeding as defined by the ISTH criteria during triple antithrombotic therapy and within 1 year

Secondary: incidence of other non-major bleeding events during triple antithrombotic therapy and within 1 year

LVT, left ventricular thrombus; ISTH, International Society on Thrombosis and Hemostasis.